CivicaScript LLC, a nonprofit focused on bringing low-cost generic medicines to US patients, announced on Thursday that it has launched its droxidopa in the United States.
Droxidopa is intended for the treatment in adults of certain types of orthostatic dizziness, light-headedness or the 'feeling that you are about to black out'.
The company will be providing droxidopa 300mg capsules for sale to pharmacies from 10 April, priced at USD132 per bottle of 90 capsules. It has been recommended that pharmacies charge patients no more than USD153 per bottle.
CivicaScript will offer 100 mg, 200 mg and 300 mg strengths of droxidopa capsules.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets